Table 3 |
||||
Change in IOP (mmHg) from baseline to week 4 (worse eye, ANCOVA, ITT population using LOCF) | ||||
Latanoprost concentration (μg/mL) | ||||
50 | 75 | 100 | 125 | |
N | 71 | 70 | 72 | 69 |
8 a.m. IOP | ||||
LS mean change (mmHg)* | −9.72 | −9.49 | −10.04 | −9.23 |
Adjusted difference in LS mean ± SEM^{†} | 0.23 ± 0.58 | −0.32 ± 0.58 | 0.49 ± 0.58 | |
(90% CI) | (−0.72, 1.19) | (−1.27, 0.63) | (−0.47, 1.45) | |
p-value^{‡} | 0.657 | 0.289 | 0.802 | |
4 p.m. IOP | ||||
LS mean change (mmHg)* | −8.47 | −7.96 | −8.84 | −8.49 |
Adjusted difference in LS mean ± SEM^{†} | 0.51 ± 0.63 | −0.36 ± 0.62 | −0.02 ± 0.63 | |
(90% CI) | (−0.53, 1.55) | (−1.39, 0.67) | (−1.06, 1.02) | |
p-value^{‡} | 0.792 | 0.280 | 0.488 |
ANCOVA analysis of covariance, CI confidence interval, IOP intraocular pressure, LS least square, ITT intent to treat, SEM standard error of the mean.
*Adjusting for baseline IOP (covariate) with dose group and center as factors.
^{†}Higher concentration minus latanoprost 50 μg/mL; a negative difference in LS mean indicates that the higher concentration has a greater effect than latanoprost 50 μg/mL.
^{‡}One-sided p-value.
Eveleth et al.
Eveleth et al. BMC Ophthalmology 2012 12:9 doi:10.1186/1471-2415-12-9